Abstract 925P
Background
Response to immunotherapy in recurrent or metastatic head and neck squamous cell carcinoma (RM-HNSCC) varies among patients and depends on lesion features. This study evaluates the CD8 validated radiomics signature (RS) on the metastasis of RM-HNSCC patients to predict patient outcomes to nivolumab.
Methods
This study involved patients from the multi-institutional TOPNIVO phase II study (NCT03226756). At least 5 lesions per organ from each patient were delineated from baseline contrast enhanced CT scans. Features were extracted with the LIFEX software (IMIV/CEA, Orsay, France) and the RS was applied. Pre-treatment biopsies were used to quantify CD8 T-cells concentration (CD8C). The prognostic value of the CD8C and the minimum RS (mRS) were assessed, with values below the median classified as cold tumors.
Results
From 330 patients, 275 were eligible for the radiomics project, totaling 1371 lesions. CD8C was quantified from 133 patients providing a pre-treatment biopsy. CD8C was associated with PFS (HR=0.69, [0.49-0.69], P-value=0.042) and OS (HR=0.58, [0.40-0.84], P-value=0.004). The mRS was associated with OS (HR=0.70, [0.54-0.90], P-value=0.006). CD8C and mRS were independently associated with OS (HR=0.60, [0.41-0.88], P-value=0.009; HR=0.52, [0.34-0.77], P-value=0.001, multivariate analysis Table). Table: 925P
| Overall survival (HR [95%CI]) | P-value | Progression free survival (HR [95%CI]) | P-value | |
Age: ≥ 60 (vs ConclusionsThe least infiltrated lesion indicated by the mRS from metastatic lesions provide prognostic value in RM-HNSCC patients. This score could offer a valuable tool for clinicians to individualize management of RM-HNSCC under nivolumab. Clinical trial identificationNCT03226756. Editorial acknowledgementLegal entity responsible for the studyInstitut Gustave Roussy. FundingFondation ARC. DisclosureC. Even: Financial Interests, Personal, Advisory Board: BMS, MSD, Innate Pharma, Merck Serono; Financial Interests, Institutional, Advisory Board: F Star Therapeutics, Novartis, Elevar, BICARA, PDS Biotechnology, GSK, Merus; Financial Interests, Institutional, Local PI: BMS, AstraZeneca, ISA pharmaceutics, MSD, Debiopharma, Ayala, Gilead, GSK, Beigene, Takeda, Genmab, Seagen, Nykode; Financial Interests, Institutional, Coordinating PI: BMS, Novartis, sanofi. Y. Tao: Financial Interests, Institutional, Advisory Board: MSD, Bristol Myers Squibb; Financial Interests, Personal and Institutional, Funding: Onxeo, Merck; Financial Interests, Personal and Institutional, Advisory Board: Seagen. G. Lefebvre: Financial Interests, Personal and Institutional, Advisory Board: Bristol Myers Squibb; Financial Interests, Personal, Advisory Role: Merck. A. Daste: Financial Interests, Personal and Institutional, Expert Testimony: Merck; Financial Interests, Personal and Institutional, Advisory Board: Bristol Myers Squibb, Amgen; Financial Interests, Personal and Institutional, Funding: Merck. E.B. Saada: Financial Interests, Personal, Advisory Board: Merck Serono; Financial Interests, Personal, Invited Speaker: Merck Serono, MSD; Financial Interests, Coordinating PI: Novartis; Financial Interests, Institutional, Coordinating PI: Roche. J. Fayette: Financial Interests, Personal, Advisory Board: AstraZeneca, MSD, Innate Pharma, Merck, Serono, Roche, Pfizer, Hookipa; Non-Financial Interests, Principal Investigator: AstraZeneca, MSD, Pfizer, Meru, Calliditas, Isa. P. Blanchard: Financial Interests, Institutional, Invited Speaker: Ipsen, Sanofi Aventis, Janssen, MSD; Financial Interests, Personal, Invited Speaker, advisory board and speaker at conferences: Bayer; Financial Interests, Institutional, Advisory Board: Becton Dickinson; Financial Interests, Institutional, Full or part-time Employment, Editor in Chief - Clinical and Translational Radiation Oncology: ESTRO. M. Classe: Financial Interests, Personal and Institutional, Member: Sanofi. A. Auperin: Financial Interests, Personal, Advisory Board: MSD. E. Deutsch: Financial Interests, Personal, Advisory Board: Roche, Bristol Myers Squibb; Financial Interests, Personal, Funding: MSD, AstraZeneca, Boehringer Ingelheim Pharma GmbH & Co.KG; Financial Interests, Personal and Institutional, Advisory Board: Merck. All other authors have declared no conflicts of interest. Resources from the same session938TiP - Phase II TROPHY-IO-HN study of pembrolizumab ±sacituzumab govitecan in first-line recurrent /metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patientsPresenter: Amanda Psyrri Session: Poster session 03 941TiP - A phase I/IIa, open-label, dose-finding trial to evaluate safety, immunogenicity, and anti-tumour activity of VB10.16 in combination with pembrolizumab in patients with unresectable recurrent or metastatic HPV16-positive head and neck squamous cell carcinoma (R/M HNSCC)Presenter: Saira Khalique Session: Poster session 03 942TiP - A randomized controlled clinical trial of neoadjuvant immunochemotherapy vs up-front surgery in patients with locally advanced resectable oral squamous cell carcinoma (Tophill trial)Presenter: Laiping Zhong Session: Poster session 03 Resources: Abstract 945TiP - JADE: A phase (ph) III study to evaluate dostarlimab vs placebo (PBO) as sequential therapy after chemoradiation (CRT) in patients (pts) with locally advanced unresected head and neck squamous cell carcinoma (LA-HNSCC)Presenter: Jean-Pascal Machiels Session: Poster session 03 1002P - A phase Ia study of the myeloid-derived suppressor cell modulator HF1K16 in refractory and metastatic cancer patients: Preliminary efficacy and safetyPresenter: Ruofan Huang Session: Poster session 03 1003P - A first-in-human (FIH) phase I study of IPH5301, an anti-CD73 monoclonal antibody (mAb), in patients with advanced solid tumors (AST) (CHANCES, NCT05143970)Presenter: Mathilde Beaufils Session: Poster session 03 This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used. For more detailed information on the cookies we use, please check our Privacy Policy.
|